



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board
Thursday, December 12, 2024, 1:00pm
DMAS -- 600 East Broad Street

Agenda

1. **Call to Order and Introductions** – Rachel Cain, PharmD, Chair
2. **Minutes - Approval of Minutes from the September 12, 2024 meeting**
3. **New Drugs – Grid**
 - a) Aqneursa™ (levacetylleucine)
 - b) Lazcluze™ (lazertinib)
 - c) Miplyffa™ (arimoclomol)
 - d) Ojemda™ (tovorafenib) *
 - e) Voranigo® (vorasidenib)
 - f) Xdemvy™ (lotilaner)
 - g) Xolremdi® (mavorixafor)
 - h) Yorvipath® (palopegteriparatide)
4. **New Class Criteria**
 - a) Oral Oncology – Skin *
5. **Old Business**
 - a) Rezdifra™ (resmetirom)
6. **DUR Quarterly Newsletter**
7. **Prime Therapeutics Pipeline – Available on WebPortal**



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

8. Topics for Discussion

- a) Concurrent Use of Opioids and Benzodiazepines
- b) Concurrent Use of Opioids and Antipsychotics
- c) Overlaps in Opioids, Benzodiazepines and Antipsychotics
- d) Naloxone and Buprenorphine Utilization for Members on Opioids

9. Reports

- a) ProDUR
- b) RetroDUR
 - i. Recent RetroDUR Activity
 - ii. RetroDUR Criteria Estimates
- c) Utilization Analysis

10. Adjournment

DRAFT